Keyword search

Filter results by

Search Help
Currently selected filters that can be removed

Keyword(s)

Type

1 facets displayed. 0 facets selected.

Year of publication

5 facets displayed. 0 facets selected.

Survey or statistical program

1 facets displayed. 1 facets selected.
Sort Help
entries

Results

All (7)

All (7) ((7 results))

  • Articles and reports: 88F0006X2005009
    Description:

    The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.

    Release date: 2005-04-27

  • Articles and reports: 88-001-X20030047882
    Description:

    Biotechnology is an enabling technology - one that has been compared to electricity or microelectronics - because it has the potential to transform production processes, products and services in a wide range of sectors of the economy. At present, major applications of biotechnology are taking place in health, agrifood, and natural resources (e.g. forestry and mining). This survey is intended to quantify the level of industrial activity in biotechnology Research and Development by sector of application and to reveal trends in spending.

    Release date: 2003-06-05

  • Articles and reports: 88F0006X2003005
    Description:

    The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2001 Biotechnology Use and Development Survey. Within the last few years, except for the amount of financing capital raised, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 358 in 1999 to 375 in 2001. The Human Health sector outpaces all the other sectors in terms of the number of firms, human resources, biotechnology revenues, biotechnology research and development expenditures, amount of financing capital raised, and the number of products in the pipeline. Contrary to medium-sized and large firms where the personnel is more homogenous, small firms employ mostly highly-qualified workers. The 2001 data show a maturing trend in small firms. Most firms could not hire enough people to fill all their vacancies (estimated at 953 positions in Canada) for the 2001 year.

    Release date: 2003-03-28

  • Articles and reports: 88F0006X2002003
    Description:

    This is the final of three papers providing data and an overview of the results of the Biotechnology Use and Development Survey - 1999. Readers are encouraged to use the data. The next edition of the Biotechnology Use and Development Survey - 2001 is expected to be administered in the spring of 2002 with results available early in 2003.

    Release date: 2002-03-28

  • Articles and reports: 88F0006X2001012
    Description:

    As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.

    Release date: 2001-09-25

  • Articles and reports: 88F0006X2001011
    Description:

    This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.

    Release date: 2001-08-28

  • Articles and reports: 88-001-X20000027928
    Description:

    The statistics presented in this bulletin are derived from our latest survey of research and development activities in Canadian industry. In 1997, a decision was made to reduce response burden by eliminating the short survey forms in favour of using administrative data. Biotechnology data are not currently available from administrative data. Therefore, only those research and development performers with over one million dollars of intramural research and development expenditures are included in these statistics. Based on 1995, the last year of full coverage, 87.6% of biotechnology research and development expenditures were made by these large performers, which represented 24% of all companies reporting biotechnology research and development activities.

    Release date: 2000-06-16
Data (0)

Data (0) (0 results)

No content available at this time.

Analysis (7)

Analysis (7) ((7 results))

  • Articles and reports: 88F0006X2005009
    Description:

    The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.

    Release date: 2005-04-27

  • Articles and reports: 88-001-X20030047882
    Description:

    Biotechnology is an enabling technology - one that has been compared to electricity or microelectronics - because it has the potential to transform production processes, products and services in a wide range of sectors of the economy. At present, major applications of biotechnology are taking place in health, agrifood, and natural resources (e.g. forestry and mining). This survey is intended to quantify the level of industrial activity in biotechnology Research and Development by sector of application and to reveal trends in spending.

    Release date: 2003-06-05

  • Articles and reports: 88F0006X2003005
    Description:

    The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2001 Biotechnology Use and Development Survey. Within the last few years, except for the amount of financing capital raised, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 358 in 1999 to 375 in 2001. The Human Health sector outpaces all the other sectors in terms of the number of firms, human resources, biotechnology revenues, biotechnology research and development expenditures, amount of financing capital raised, and the number of products in the pipeline. Contrary to medium-sized and large firms where the personnel is more homogenous, small firms employ mostly highly-qualified workers. The 2001 data show a maturing trend in small firms. Most firms could not hire enough people to fill all their vacancies (estimated at 953 positions in Canada) for the 2001 year.

    Release date: 2003-03-28

  • Articles and reports: 88F0006X2002003
    Description:

    This is the final of three papers providing data and an overview of the results of the Biotechnology Use and Development Survey - 1999. Readers are encouraged to use the data. The next edition of the Biotechnology Use and Development Survey - 2001 is expected to be administered in the spring of 2002 with results available early in 2003.

    Release date: 2002-03-28

  • Articles and reports: 88F0006X2001012
    Description:

    As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.

    Release date: 2001-09-25

  • Articles and reports: 88F0006X2001011
    Description:

    This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.

    Release date: 2001-08-28

  • Articles and reports: 88-001-X20000027928
    Description:

    The statistics presented in this bulletin are derived from our latest survey of research and development activities in Canadian industry. In 1997, a decision was made to reduce response burden by eliminating the short survey forms in favour of using administrative data. Biotechnology data are not currently available from administrative data. Therefore, only those research and development performers with over one million dollars of intramural research and development expenditures are included in these statistics. Based on 1995, the last year of full coverage, 87.6% of biotechnology research and development expenditures were made by these large performers, which represented 24% of all companies reporting biotechnology research and development activities.

    Release date: 2000-06-16
Reference (0)

Reference (0) (0 results)

No content available at this time.

Date modified: